[
    [
        {
            "time": "2021-04-30",
            "original_text": "A股主力资金流向（4月30日）：医药股获资金爆买",
            "features": {
                "keywords": [
                    "A股",
                    "主力资金",
                    "医药股",
                    "资金流向"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股主力资金流向（4月30日）：医药股获资金爆买",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "东莞证券维持华熙生物推荐评级，2021年一季报点评：功能性护肤品持续高增长，功能性食品强劲起势",
            "features": {
                "keywords": [
                    "华熙生物",
                    "一季报",
                    "功能性护肤",
                    "功能性食品",
                    "高增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "化妆品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东莞证券维持华熙生物推荐评级，2021年一季报点评：功能性护肤品持续高增长，功能性食品强劲起势",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "东方财富证券维持华熙生物增持评级，2021年一季报点评，近期获32份券商研报关注，目标均价跌幅14.15%",
            "features": {
                "keywords": [
                    "华熙生物",
                    "一季报",
                    "券商研报",
                    "目标均价跌幅"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "化妆品"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "东方财富证券维持华熙生物增持评级，2021年一季报点评，近期获32份券商研报关注，目标均价跌幅14.15%",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "东吴证券维持华熙生物买入评级：营收+111%，化妆品业务高速增长，医美业务提速可期，玻尿酸龙头壁垒高筑",
            "features": {
                "keywords": [
                    "华熙生物",
                    "买入评级",
                    "营收增长",
                    "化妆品",
                    "医美",
                    "玻尿酸"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "化妆品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券维持华熙生物买入评级：营收+111%，化妆品业务高速增长，医美业务提速可期，玻尿酸龙头壁垒高筑",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "大股东清仓式减持一周套现30亿，医美股不香了？减持股份",
            "features": {
                "keywords": [
                    "大股东",
                    "减持",
                    "医美股",
                    "套现"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "大股东清仓式减持一周套现30亿，医美股不香了？减持股份",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "明星私募一季度调仓：冯柳现身25家公司持仓超300亿，高瓴礼仁新进安图生物、伊利",
            "features": {
                "keywords": [
                    "明星私募",
                    "冯柳",
                    "高瓴礼仁",
                    "安图生物",
                    "伊利"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "消费"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "明星私募一季度调仓：冯柳现身25家公司持仓超300亿，高瓴礼仁新进安图生物、伊利",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "多位明星基金经理增持，医药板块上涨的空间还大吗?丨牛熊眼",
            "features": {
                "keywords": [
                    "明星基金经理",
                    "增持",
                    "医药板块",
                    "上涨空间"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "多位明星基金经理增持，医药板块上涨的空间还大吗?丨牛熊眼",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]